EGFR-IN-169 is an epidermal growth factor receptor (EGFR) inhibitor derived from ginsenoside, with an IC50 of 5.19 µM. It disrupts colorectal cancer cell migration and growth by inhibiting the EGFR-mediated RalA/EMT pathway. With an IC50 of 4.46 µM against HCT-116 cells and a selectivity index (SI) of 16.92, EGFR-IN-169 also inhibits CDKs, induces G0/G1 cell cycle arrest, and suppresses cell migration and invasion. Additionally, EGFR-IN-169 reduces mitochondrial membrane potential, induces apoptosis and reactive oxygen species (ROS) production. It is applicable in cancer research, particularly for colorectal cancer.
Target:
ROS|||Bcl-2 Family|||Apoptosis|||EGFR|||CDK
* VAT and and shipping costs not included. Errors and price changes excepted
